NASDAQ · TECX
Tectonic Therapeutic, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for TECX: Nov 5, 2026
Tectonic Therapeutic, Inc. Common Stock is estimated to report earnings on 11/05/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 5 analysts' forecasts, the consensus EPS forecast for the quarter is $-1.38. The reported EPS for the same quarter last year was $-1.02.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-1.38 | $-1.25 | $-1.54 | 5 |
| Dec 2026 | $-1.38 | $-1.33 | $-1.45 | 5 |
| Mar 2027 | $-1.44 | $-1.38 | $-1.49 | 2 |
| Jun 2027 | $-1.50 | $-1.45 | $-1.55 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
BNK Invest · RTTNews · Fintel · The Motley Fool- BNK Invest · Sep 1, 3:24 PM EDTNoteworthy Tuesday Option Activity: AGX, NN, TECXLooking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Argan Inc (Symbol: AGX), where a total volume of 5,539 contracts has been traded thus far today, a contract volume which is representative of approximately 553,9
- RTTNews · Jul 6, 5:51 AM EDT5 Biotech Stocks That Delivered 100% To 300% Gains: Did Your Winning Trades Offset Portfolio Losses?(RTTNews) – Even with strong research and disciplined stock selection, an investor may not get every stock pick right. As legendary investor Peter Lynch once said, "In this business, if you're good, you're right six times out of ten. You're never going to be right nine times out
- RTTNews · Jul 3, 1:15 AM EDTTop Biotech Gainers: PPCB Launches Share Buyback, VRXA Partners With ATUM, SLS On Watch(RTTNews) – Today's top gainers include SL Science, which was recently listed on the Nasdaq; Chemomab, gearing up for a Phase 3 trial in primary sclerosing cholangitis; Propanc, following the launch of a share repurchase program; and Tectonic, drawing investor attention ahead of
- RTTNews · Jun 11, 2:24 AM EDTTectonic Completes Enrollment In Phase 2 APEX Trial For TX-45 In Pulmonary Hypertension Subtype(RTTNews) – Tectonic Therapeutics Inc. (TECX), a clinical-stage biotechnology company, on Wednesday announced completion of enrollment in the Phase 2 APEX trial for TX45 in treating pulmonary hypertension associated with heart failure with preserved ejection fraction.
- Fintel · May 26, 8:02 PM EDTRaymond James Upgrades Tectonic Therapeutic (TECX)Fintel reports that on May 26, 2026, Raymond James upgraded their outlook for Tectonic Therapeutic (NasdaqGM:TECX) from Outperform to Strong Buy. Analyst Price Forecast Suggests 172.83% Upside
- Fintel · Apr 14, 8:05 PM EDTStifel Initiates Coverage of Tectonic Therapeutic (TECX) with Buy RecommendationFintel reports that on April 14, 2026, Stifel initiated coverage of Tectonic Therapeutic (NasdaqGM:TECX) with a Buy recommendation. Analyst Price Forecast Suggests 166.85% Upside
- RTTNews · Feb 27, 3:04 AM ESTTectonic Therapeutics' Q4 Net Loss Widens; Phase 2 APEX Trial Data Due In 2026(RTTNews) – Tectonic Therapeutics, Inc. (TECX), a clinical-stage biotechnology company, reported fourth-quarter and full-year 2025 results and provided an update on the progress of its clinical pipeline, including recent achievements and upcoming milestones.
- RTTNews · Oct 30, 12:19 PM EDTTectonic Therapeutic Surges 12% On Positive Phase 1b Topline Data For TX45(RTTNews) – Tectonic Therapeutic, Inc. (TECX) jumped 12.33% to $20.92, gaining $2.30, after announcing positive topline results from its Phase 1b Part B clinical trial of TX45 in patients with Group 2 pulmonary hypertension associated with heart failure with reduced ejection frac
- RTTNews · Oct 30, 12:44 AM EDTTECX, GKOS, GH, ALGN, NMRA Surge After Hours On Clinical Data And Earnings(RTTNews) – Several healthcare and life sciences names posted notable gains in after-hours trading, driven by clinical updates, earnings releases, and in some cases, unexplained momentum.
- The Motley Fool · Aug 7, 11:04 PM EDTTectonic (TECX) Q2 R&D Soars 142%Research and development spending increased 142.3% year over year to $17.2 million in Q2 2025, compared to $7.1 million in Q2 2024, driven by clinical trial activity.
- Quiver Quantitative · Jun 30, 8:14 AM EDTTectonic Therapeutic, Inc. Added to Russell 3000® Index Following Annual ReconstitutionTectonic Therapeutic, Inc. has been added to the Russell 3000® Index following the 2025 annual reconstitution.
- Fintel · Jun 6, 8:02 PM EDTLifeSci Capital Initiates Coverage of Tectonic Therapeutic (TECX) with Outperform RecommendationFintel reports that on June 6, 2025, LifeSci Capital initiated coverage of Tectonic Therapeutic (NasdaqGM:TECX) with a Outperform recommendation.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Tectonic Therapeutic, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.